This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Abbott T.R., Qi L.S. et al.: Development of CRISPR as an Antiviral Strategy to Combat SARS-CoV-2 and Influenza. Cell, 181, 865–876.e12 (2020)AbbottT.R.QiL.S.Development of CRISPR as an Antiviral Strategy to Combat SARS-CoV-2 and InfluenzaCell181865876.e12202010.1016/j.cell.2020.04.020718986232353252Search in Google Scholar
Abudayyeh O.O., Zhang F. et al.: RNA targeting with CRISPR-Cas13. Nature, 550, 280–284 (2017)AbudayyehO.O.ZhangF.RNA targeting with CRISPR-Cas13Nature550280284201710.1038/nature24049570665828976959Search in Google Scholar
Ahmed A., Wilcox R.A. et al.: Ruxolitinib in adult patients with secondary haemophagocytic lymphohistiocytosis: an open-label, single-centre, pilot trial. Lancet Haematol, 6, e630–e637 (2019)AhmedA.WilcoxR.A.Ruxolitinib in adult patients with secondary haemophagocytic lymphohistiocytosis: an open-label, single-centre, pilot trialLancet Haematol6e630e637201910.1016/S2352-3026(19)30156-5805498131537486Search in Google Scholar
Albeituni S., Verbist K.C., Tedrick P.E., Tillman H., Picarsic J., Bassett R., Nichols K.E.: Mechanisms of action of ruxolitinib in murine models of hemophagocytic lymphohistiocytosis. Blood, 134, 147–159 (2019)AlbeituniS.VerbistK.C.TedrickP.E.TillmanH.PicarsicJ.BassettR.NicholsK.E.Mechanisms of action of ruxolitinib in murine models of hemophagocytic lymphohistiocytosisBlood134147159201910.1182/blood.2019000761662497231015190Search in Google Scholar
Andreani J., Raoult D. et al.: In vitro testing of combined hydroxychloroquine and azithromycin on SARS-CoV-2 shows synergistic effect. Microb. Pathog. 145, 104228 (2020)AndreaniJ.RaoultD.In vitro testing of combined hydroxychloroquine and azithromycin on SARS-CoV-2 shows synergistic effectMicrob. Pathog.145104228202010.1016/j.micpath.2020.104228718274832344177Search in Google Scholar
Antinori S., Galli M. et al.: Compassionate remdesivir treatment of severe Covid-19 pneumonia in intensive care unit (ICU) and Non-ICU patients: Clinical outcome and differences in post_treatment hospitalisation status. Pharmacol. Res, 158, 104899–104899 (2020)AntinoriS.GalliM.Compassionate remdesivir treatment of severe Covid-19 pneumonia in intensive care unit (ICU) and Non-ICU patients: Clinical outcome and differences in post_treatment hospitalisation statusPharmacol. Res158104899104899202010.1016/j.phrs.2020.104899721296332407959Search in Google Scholar
Antwi-Amoabeng D., Kanji Z., Ford B., Beutler B.D., Riddle M.S., Siddiqui F.: Clinical Outcomes in COVID-19 Patients Treated with Tocilizumab: An Individual Patient Data Systematic Review. J. Med. Virol. (2020)Antwi-AmoabengD.KanjiZ.FordB.BeutlerB.D.RiddleM.S.SiddiquiF.Clinical Outcomes in COVID-19 Patients Treated with Tocilizumab: An Individual Patient Data Systematic ReviewJ. Med. Virol.202010.1002/jmv.26038728061532436994Search in Google Scholar
Atal S., Fatima Z.: IL-6 Inhibitors in the Treatment of Serious COVID-19: A Promising Therapy? Pharmaceut. Med. 1–9 (2020)AtalS.FatimaZ.IL-6 Inhibitors in the Treatment of Serious COVID-19: A Promising Therapy?Pharmaceut. Med.19202010.1007/s40290-020-00342-z729293632535732Search in Google Scholar
Báez-Santos Y.M., St John S.E., Mesecar A.D.: The SARS-coronavirus papain-like protease: structure, function and inhibition by designed antiviral compounds. Antiviral Res. 115, 21–38 (2015)Báez-SantosY.M.St JohnS.E.MesecarA.D.The SARS-coronavirus papain-like protease: structure, function and inhibition by designed antiviral compoundsAntiviral Res.1152138201510.1016/j.antiviral.2014.12.015589674925554382Search in Google Scholar
Barnard D.L., Sidwell R.W. et al.: Enhancement of the infectivity of SARS-CoV in BALB/c mice by IMP dehydrogenase inhibitors, including ribavirin. Antiviral Res. 71, 53–63 (2006)BarnardD.L.SidwellR.W.Enhancement of the infectivity of SARS-CoV in BALB/c mice by IMP dehydrogenase inhibitors, including ribavirinAntiviral Res.715363200610.1016/j.antiviral.2006.03.001711426116621037Search in Google Scholar
Batlle D., Wysocki J., Satchell K.: Soluble angiotensin-converting enzyme 2: a potential approach for coronavirus infection therapy? Clini. Sci. 134, 543–545 (2020)BatlleD.WysockiJ.SatchellK.Soluble angiotensin-converting enzyme 2: a potential approach for coronavirus infection therapy?Clini. Sci.134543545202010.1042/CS2020016332167153Search in Google Scholar
Becares M., Pascual-Iglesias A., Nogales A., Sola I., Enjuanes L., Zuñiga S.: Mutagenesis of coronavirus nsp14 reveals its potential role in modulation of the innate immune response. J. Virol, 90, 5399–5414 (2016)BecaresM.Pascual-IglesiasA.NogalesA.SolaI.EnjuanesL.ZuñigaS.Mutagenesis of coronavirus nsp14 reveals its potential role in modulation of the innate immune responseJ. Virol9053995414201610.1128/JVI.03259-15493475527009949Search in Google Scholar
Bechman K., Subesinghe S., Norton S., Atzeni F., Galli M., Cope A.P., Winthrop K.L., Galloway J.B.: A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis. Rheumatology, 58, 1755–1766 (2019)BechmanK.SubesingheS.NortonS.AtzeniF.GalliM.CopeA.P.WinthropK.L.GallowayJ.B.A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritisRheumatology5817551766201910.1093/rheumatology/kez08730982883Search in Google Scholar
Beck B.R., Shin B., Choi Y., Park S., Kang K.: Predicting commercially available antiviral drugs that may act on the novel coronavirus (SARS-CoV-2) through a drug-target interaction deep learning model. Comput. Struct. Biotechnol. J. 18, 784–790 (2020)BeckB.R.ShinB.ChoiY.ParkS.KangK.Predicting commercially available antiviral drugs that may act on the novel coronavirus (SARS-CoV-2) through a drug-target interaction deep learning modelComput. Struct. Biotechnol. J.18784790202010.1016/j.csbj.2020.03.025711854132280433Search in Google Scholar
Beigel J.H., Tomashek K.M., Dodd L.E.: Remdesivir for the Treatment of Covid-19 – Preliminary Report. N. Engl. J. Med. (2020)BeigelJ.H.TomashekK.M.DoddL.E.Remdesivir for the Treatment of Covid-19 – Preliminary ReportN. Engl. J. Med.202010.1056/NEJMoa2007764726278832445440Search in Google Scholar
Binois Y., Hachad H., Salem J.-E., Charpentier J., Lebrun-Vignes B., Pène F., Cariou A., Chiche J.-D., Mira J.-P., Nguyen L.S.: Acute kidney injury associated with lopinavir/ritonavir combined therapy in patients with Covid-19. Kidney Int. Rep. (2020)BinoisY.HachadH.SalemJ.-E.CharpentierJ.Lebrun-VignesB.PèneF.CariouA.ChicheJ.-D.MiraJ.-P.NguyenL.S.Acute kidney injury associated with lopinavir/ritonavir combined therapy in patients with Covid-19Kidney Int. Rep.202010.1016/j.ekir.2020.07.035740992532838087Search in Google Scholar
Blaising J., Lévy P.L., Polyak S.J., Stanifer M., Boulant S., Pécheur E.-I.: Arbidol inhibits viral entry by interfering with| clathrin-dependent trafficking. Antiviral Res. 100, 215–219 (2013)BlaisingJ.LévyP.L.PolyakS.J.StaniferM.BoulantS.PécheurE.-I.Arbidol inhibits viral entry by interfering with| clathrin-dependent traffickingAntiviral Res.100215219201310.1016/j.antiviral.2013.08.00823981392Search in Google Scholar
Blaising J., Polyak S.J., Pécheur E.-I.: Arbidol as a broad-spectrum antiviral: An update. Antiviral Res. 107, 84–94 (2014)BlaisingJ.PolyakS.J.PécheurE.-I.Arbidol as a broad-spectrum antiviral: An updateAntiviral Res.1078494201410.1016/j.antiviral.2014.04.006711388524769245Search in Google Scholar
Boriskin Y.S., Leneva I.A., Pécheur E.I., Polyak S.: Arbidol: A Broad-Spectrum Antiviral Compound that Blocks Viral Fusion. Curr. Med. Chem, 15, 997–1005 (2008)BoriskinY.S.LenevaI.A.PécheurE.I.PolyakS.Arbidol: A Broad-Spectrum Antiviral Compound that Blocks Viral FusionCurr. Med. Chem159971005200810.2174/09298670878404965818393857Search in Google Scholar
Bouvet M., Debarnot C., Imbert I., Selisko B., Snijder E.J., Canard B., Decroly E.: In vitro reconstitution of SARS-coronavirus mRNA cap methylation. PLoS Path, 6, e1000863-e1000863 (2010)BouvetM.DebarnotC.ImbertI.SeliskoB.SnijderE.J.CanardB.DecrolyE.In vitro reconstitution of SARS-coronavirus mRNA cap methylationPLoS Path6e1000863e1000863201010.1371/journal.ppat.1000863285870520421945Search in Google Scholar
Broglie L., Pommert L., Rao S., Thakar M., Phelan R., Margolis D., Talano J.: Ruxolitinib for treatment of refractory hemophagocytic lymphohistiocytosis. Blood advances, 1, 1533–1536 (2017)BroglieL.PommertL.RaoS.ThakarM.PhelanR.MargolisD.TalanoJ.Ruxolitinib for treatment of refractory hemophagocytic lymphohistiocytosisBlood advances115331536201710.1182/bloodadvances.2017007526572846629296794Search in Google Scholar
Bryan M.C., Rajapaksa N.S.: Kinase Inhibitors for the Treatment of Immunological Disorders: Recent Advances. J. Med. Chem. 61, 9030–9058 (2018)BryanM.C.RajapaksaN.S.Kinase Inhibitors for the Treatment of Immunological Disorders: Recent AdvancesJ. Med. Chem.6190309058201810.1021/acs.jmedchem.8b0066729870256Search in Google Scholar
Cai Q., Liu L. et al.: Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study. Engineering, (2020)CaiQ.LiuL.Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control StudyEngineering202010.1016/j.eng.2020.03.007718579532346491Search in Google Scholar
Caly L., Druce J.D., Catton M.G., Jans D.A., Wagstaff K.M.: The FDA-approved Drug Ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res. 178, 104787 (2020)CalyL.DruceJ.D.CattonM.G.JansD.A.WagstaffK.M.The FDA-approved Drug Ivermectin inhibits the replication of SARS-CoV-2 in vitroAntiviral Res.178104787202010.1016/j.antiviral.2020.104787712905932251768Search in Google Scholar
Cantini F., Niccoli L., Matarrese D., Nicastri E., Stobbione P., Goletti D.: Baricitinib therapy in COVID-19: A pilot study on safety and clinical impact. J. Infec. 81, 318–356 (2020)CantiniF.NiccoliL.MatarreseD.NicastriE.StobbioneP.GolettiD.Baricitinib therapy in COVID-19: A pilot study on safety and clinical impactJ. Infec.81318356202010.1016/j.jinf.2020.04.017717707332333918Search in Google Scholar
Cao B., Wang C. et al.: A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. N. Engl. J. Med. 382, 1787–179 (2020)CaoB.WangC.A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19N. Engl. J. Med.3821787179202010.1056/NEJMoa2001282712149232187464Search in Google Scholar
Cao Y., Zhou J. et al.: Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial. J. Allergy Clin. Immunol. 146, 137–146.e133 (2020)CaoY.ZhouJ.Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trialJ. Allergy Clin. Immunol.146137146.e133202010.1016/j.jaci.2020.05.019725010532470486Search in Google Scholar
Capochiani E., Bocchia M. et al.: Ruxolitinib Rapidly Reduces Acute Respiratory Distress Syndrome in COVID-19 Disease. Analysis of Data Collection From RESPIRE Protocol. Front. Med, 7, 466 (2020)CapochianiE.BocchiaM.Ruxolitinib Rapidly Reduces Acute Respiratory Distress Syndrome in COVID-19 Disease. Analysis of Data Collection From RESPIRE ProtocolFront. Med7466202010.3389/fmed.2020.00466741751232850921Search in Google Scholar
Casadevall A., Pirofski L.-A.: The convalescent sera option for containing COVID-19. J. Clin. Invest. 130, 1545–1548 (2020)CasadevallA.PirofskiL.-A.The convalescent sera option for containing COVID-19J. Clin. Invest.13015451548202010.1172/JCI138003710892232167489Search in Google Scholar
Chaccour C., Hammann F., Ramón-García S., Rabinovich N.R.: Ivermectin and COVID-19: Keeping Rigor in Times of Urgency. Am. J. Trop. Med. Hyg. 102, 1156–1157 (2020)ChaccourC.HammannF.Ramón-GarcíaS.RabinovichN.R.Ivermectin and COVID-19: Keeping Rigor in Times of UrgencyAm. J. Trop. Med. Hyg.10211561157202010.4269/ajtmh.20-0271725311332314704Search in Google Scholar
Chaccour C., Hammann F., Ramón-García S., Rabinovich N.R.: Ivermectin and Novel Coronavirus Disease (COVID-19): Keeping Rigor in Times of Urgency. Am. J. Trop. Med. Hyg.(2020)ChaccourC.HammannF.Ramón-GarcíaS.RabinovichN.R.Ivermectin and Novel Coronavirus Disease (COVID-19): Keeping Rigor in Times of UrgencyAm. J. Trop. Med. Hyg.202010.4269/ajtmh.20-0271725311332314704Search in Google Scholar
Chan J.F.-W., Yuen K.-Y. et al.: Treatment With Lopinavir/Ritonavir or Interferon-β1b Improves Outcome of MERS-CoV Infection in a Nonhuman Primate Model of Common Marmoset. J. Inf. Dis. 212, 1904–1913 (2015)ChanJ.F.-W.YuenK.-Y.Treatment With Lopinavir/Ritonavir or Interferon-β1b Improves Outcome of MERS-CoV Infection in a Nonhuman Primate Model of Common MarmosetJ. Inf. Dis.21219041913201510.1093/infdis/jiv392710739526198719Search in Google Scholar
Chandwani A., Shuter J.: Lopinavir/ritonavir in the treatment of HIV-1 infection: a review. Ther. Clin. Risk Manag. 4, 1023–1033 (2008)ChandwaniA.ShuterJ.Lopinavir/ritonavir in the treatment of HIV-1 infection: a reviewTher. Clin. Risk Manag.410231033200810.2147/TCRM.S3285262140319209283Search in Google Scholar
Chao J.Y., Derespina K.R., Herold B.C., Goldman D.L., Aldrich M., Weingarten J., Ushay H.M., Cabana M.D., Medar S.S.: Clinical Characteristics and Outcomes of Hospitalized and Critically Ill Children and Adolescents with Coronavirus Disease 2019 (COVID-19) at a Tertiary Care Medical Center in New York City. J. Ped. 223, 14–19.e2 (2020)ChaoJ.Y.DerespinaK.R.HeroldB.C.GoldmanD.L.AldrichM.WeingartenJ.UshayH.M.CabanaM.D.MedarS.S.Clinical Characteristics and Outcomes of Hospitalized and Critically Ill Children and Adolescents with Coronavirus Disease 2019 (COVID-19) at a Tertiary Care Medical Center in New York CityJ. Ped.2231419.e2202010.1016/j.jpeds.2020.05.006721294732407719Search in Google Scholar
Chen C., Wang X. et al.: Favipiravir versus Arbidol for COVID-19: A Randomized Clinical Trial. medRxiv, 2020.2003. 2017.20037432 (2020)ChenC.WangX.Favipiravir versus Arbidol for COVID-19: A Randomized Clinical TrialmedRxiv2020.2003. 2017.20037432202010.1101/2020.03.17.20037432Search in Google Scholar
Chen J., Lu H. et al.: A pilot study of hydroxychloroquine in treatment of patients with common coronavirus disease-19 (COVID-19). J. Zhejiang University (Med. Sci.), 49 (2020)ChenJ.LuH.A pilot study of hydroxychloroquine in treatment of patients with common coronavirus disease-19 (COVID-19)J. Zhejiang University (Med. Sci.)492020Search in Google Scholar
Chen L., Xiong J., Bao L., Shi Y.: Convalescent plasma as a potential therapy for COVID-19. Lancet Infect. Dis. 20, 398–400 (2020)ChenL.XiongJ.BaoL.ShiY.Convalescent plasma as a potential therapy for COVID-19Lancet Infect. Dis.20398400202010.1016/S1473-3099(20)30141-9712821832113510Search in Google Scholar
Chen Y., Guo D.: Molecular mechanisms of coronavirus RNA capping and methylation. Virologica Sinica, 31, 3–11 (2016)ChenY.GuoD.Molecular mechanisms of coronavirus RNA capping and methylationVirologica Sinica31311201610.1007/s12250-016-3726-4709137826847650Search in Google Scholar
Chen Y., Guo D. et al.: Biochemical and structural insights into the mechanisms of SARS coronavirus RNA ribose 2′-O-methylation by nsp16/nsp10 protein complex. PLoS Path. 7, e1002294–e1002294 (2011)ChenY.GuoD.Biochemical and structural insights into the mechanisms of SARS coronavirus RNA ribose 2′-O-methylation by nsp16/nsp10 protein complexPLoS Path.7e1002294e1002294201110.1371/journal.ppat.1002294319284322022266Search in Google Scholar
Chowdhury M.D.S., Rathod J., Gernsheimer J.: A Rapid Systematic Review of Clinical Trials Utilizing Chloroquine and Hydroxychloroquine as a Treatment for COVID-19. Acad. Emerg. Med. 27, 493–504 (2020)ChowdhuryM.D.S.RathodJ.GernsheimerJ.A Rapid Systematic Review of Clinical Trials Utilizing Chloroquine and Hydroxychloroquine as a Treatment for COVID-19Acad. Emerg. Med.27493504202010.1111/acem.14005726750732359203Search in Google Scholar
Choy K.-T., Yen H.-L. et al.: Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro. Antiviral Res. 178, 104786 (2020)ChoyK.-T.YenH.-L.Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitroAntiviral Res.178104786202010.1016/j.antiviral.2020.104786712738632251767Search in Google Scholar
Colaneri M., Bogliolo L., Valsecchi P., Sacchi P., Zuccaro V., Brandolino F., Montecucco C., Mojoli F., Giusti E.M., Bruno R.: Tocilizumab for treatment of severe COVID-19 patients: preliminary results from SMAtteo COvid19 REgistry (SMACORE). Microorganisms, 8, (2020)ColaneriM.BoglioloL.ValsecchiP.SacchiP.ZuccaroV.BrandolinoF.MontecuccoC.MojoliF.GiustiE.M.BrunoR.Tocilizumab for treatment of severe COVID-19 patients: preliminary results from SMAtteo COvid19 REgistry (SMACORE)Microorganisms8202010.3390/microorganisms8050695728550332397399Search in Google Scholar
Cyranoski D.: China is promoting coronavirus treatments based on unproven traditional medicines. Nature, (2020).CyranoskiD.China is promoting coronavirus treatments based on unproven traditional medicinesNature202010.1038/d41586-020-01284-x32376938Search in Google Scholar
Dastan F., Tabarsi P. et al.: Promising Effects of Tocilizumab in COVID-19: A Non-Controlled, Prospective Clinical Trial. Int. Immunopharmacol. 88, 106869 (2020)DastanF.TabarsiP.Promising Effects of Tocilizumab in COVID-19: A Non-Controlled, Prospective Clinical TrialInt. Immunopharmacol.88106869202010.1016/j.intimp.2020.106869740220632889241Search in Google Scholar
Deng L., Li C., Zeng Q., Liu X., Li X., Zhang H., Hong Z., Xia J.: Arbidol combined with LPV/r versus LPV/r alone against Corona Virus Disease 2019: A retrospective cohort study. J. Infect. 81, e1–e5 (2020)DengL.LiC.ZengQ.LiuX.LiX.ZhangH.HongZ.XiaJ.Arbidol combined with LPV/r versus LPV/r alone against Corona Virus Disease 2019: A retrospective cohort studyJ. Infect.81e1e5202010.1016/j.jinf.2020.03.002715615232171872Search in Google Scholar
Duan K., Yang X. et al.: Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proc. Nat. Acad. Sci. USA, 117, 9490–9496 (2020)DuanK.YangX.Effectiveness of convalescent plasma therapy in severe COVID-19 patientsProc. Nat. Acad. Sci. USA11794909496202010.1073/pnas.2004168117719683732253318Search in Google Scholar
Durante-Mangoni E., Andini R., Bertolino L., Mele F., Florio L.L., Murino P., Corcione A., Zampino R.: Early experience with remdesivir in SARS-CoV-2 pneumonia. Infection, 1–4 (2020)Durante-MangoniE.AndiniR.BertolinoL.MeleF.FlorioL.L.MurinoP.CorcioneA.ZampinoR.Early experience with remdesivir in SARS-CoV-2 pneumoniaInfection14202010.1007/s15010-020-01448-x722943632418190Search in Google Scholar
Elfiky A.A.: Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, )and Tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking study. Life Sci. 253, 117592–117592 (2020)ElfikyA.A.Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, )and Tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking studyLife Sci.253117592117592202010.1016/j.lfs.2020.117592710264632222463Search in Google Scholar
Falzarano D., de Wit E., Martellaro C., Callison J., Munster V.J., Feldmann H.: Inhibition of novel β coronavirus replication by a combination of interferon-α2b and ribavirin. Sci. Rep. 3, 1686–1686 (2013)FalzaranoD.de WitE.MartellaroC.CallisonJ.MunsterV.J.FeldmannH.Inhibition of novel β coronavirus replication by a combination of interferon-α2b and ribavirinSci. Rep.316861686201310.1038/srep01686362941223594967Search in Google Scholar
Falzarano D., Feldmann H. et al.: Treatment with interferon-alpha 2b and ribavirin improves outcome in MERS-CoV-infected rhesus macaques. Nat. Med. 10, 1313–7 (2013)FalzaranoD.FeldmannH.Treatment with interferon-alpha 2b and ribavirin improves outcome in MERS-CoV-infected rhesus macaquesNat. Med.1013137201310.1038/nm.3362409390224013700Search in Google Scholar
Fantini J., Di Scala C., Chahinian H., Yahi N.: Structural and molecular modelling studies reveal a new mechanism of action of chloroquine and hydroxychloroquine against SARS-CoV-2 infection. Int. J. Antimicrob. Agents, 55, 105960 (2020)FantiniJ.Di ScalaC.ChahinianH.YahiN.Structural and molecular modelling studies reveal a new mechanism of action of chloroquine and hydroxychloroquine against SARS-CoV-2 infectionInt. J. Antimicrob. Agents55105960202010.1016/j.ijantimicag.2020.105960712867832251731Search in Google Scholar
Favalli E.G., Biggioggero M., Maioli G., Caporali R.: Baricitinib for COVID-19: a suitable treatment? Lancet Infect. Dis. 9, 1012–1013 (2020)FavalliE.G.BiggioggeroM.MaioliG.CaporaliR.Baricitinib for COVID-19: a suitable treatment?Lancet Infect. Dis.910121013202010.1016/S1473-3099(20)30262-0727079432251638Search in Google Scholar
Franzetti M., Piconi S. et al.: Interleukin-1 receptor antagonist anakinra in association with remdesivir in severe Coronavirus disease 2019: A case report. Int. J. Infect.Dis. 97, 215–218 (2020)FranzettiM.PiconiS.Interleukin-1 receptor antagonist anakinra in association with remdesivir in severe Coronavirus disease 2019: A case reportInt. J. Infect.Dis.97215218202010.1016/j.ijid.2020.05.050722889032422376Search in Google Scholar
Freije C.A., Sabeti P.C. et al.: Programmable Inhibition and Detection of RNA Viruses Using Cas13. Mol. Cell, 76, 826–837.e811 (2019)FreijeC.A.SabetiP.C.Programmable Inhibition and Detection of RNA Viruses Using Cas13Mol. Cell76826837.e811201910.1016/j.molcel.2019.09.013742262731607545Search in Google Scholar
Furuta Y., Komeno T., Nakamura T.: Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase. Proc. Jpn. Acad. Ser. B. Phys. Biol. Sci. 93, 449–463 (2017)FurutaY.KomenoT.NakamuraT.Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymeraseProc. Jpn. Acad. Ser. B. Phys. Biol. Sci.93449463201710.2183/pjab.93.027571317528769016Search in Google Scholar
Gao J., Tian Z., Yang X.: Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. BioSci. Trends, 14, 72–73 (2020)GaoJ.TianZ.YangX.Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studiesBioSci. Trends147273202010.5582/bst.2020.0104732074550Search in Google Scholar
Gaspari V., Zengarini C., Greco S., Vangeli V., Mastroianni A.: Side effects of ruxolitinib in patients with SARS-CoV-2 infection: Two case reports. Int. J. Antimicrob. Agents, 56, 106023–106023 (2020)GaspariV.ZengariniC.GrecoS.VangeliV.MastroianniA.Side effects of ruxolitinib in patients with SARS-CoV-2 infection: Two case reportsInt. J. Antimicrob. Agents56106023106023202010.1016/j.ijantimicag.2020.106023724375432450201Search in Google Scholar
Gautret P., Raoult D. et al.: Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int. J. Antimicrob. Agents, 56, 105949 (2020)GautretP.RaoultD.Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trialInt. J. Antimicrob. Agents56105949202010.1016/j.ijantimicag.2020.105949710254932205204Search in Google Scholar
George J., Mattapallil J.J.: Interferon-α Subtypes As an Adjunct Therapeutic Approach for Human Immunodeficiency Virus Functional Cure. Front. Immun. 9, 299–299 (2018)GeorgeJ.MattapallilJ.J.Interferon-α Subtypes As an Adjunct Therapeutic Approach for Human Immunodeficiency Virus Functional CureFront. Immun.9299299201810.3389/fimmu.2018.00299582715729520278Search in Google Scholar
Gharbharan A., Rijnders B. et al.: Convalescent Plasma for COVID-19. A randomized clinical trial. medRxiv, 2020.2007. 2001.20139857 (2020)GharbharanA.RijndersB.Convalescent Plasma for COVID-19. A randomized clinical trialmedRxiv2020.2007. 2001.20139857202010.1101/2020.07.01.20139857Search in Google Scholar
Goldman J.D., Subramanian A. et al.: Remdesivir for 5 or 10 Days in Patients with Severe Covid-19. N. Engl. J. Med. (2020)GoldmanJ.D.SubramanianA.Remdesivir for 5 or 10 Days in Patients with Severe Covid-19N. Engl. J. Med.202010.1056/NEJMoa2015301737706232459919Search in Google Scholar
Gordon C.J., Tchesnokov E.P., Woolner E., Perry J.K., Feng J.Y., Porter D.P., Gotte M.: Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency. J. Biol. Chem. 295, 6785–6797. (2020)GordonC.J.TchesnokovE.P.WoolnerE.PerryJ.K.FengJ.Y.PorterD.P.GotteM.Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potencyJ. Biol. Chem.29567856797202010.1074/jbc.RA120.013679724269832284326Search in Google Scholar
Gorial F.I., Mashhadani S., Sayaly H.M., Dakhil B.D., AlMashhadani M.M., Aljabory A.M., Abbas H.M., Ghanim M., Rasheed J.I.: Effectiveness of Ivermectin as add-on Therapy in COVID-19 Management (Pilot Trial). medRxiv, 2020.2007.2007.20145979 (2020)GorialF.I.MashhadaniS.SayalyH.M.DakhilB.D.AlMashhadaniM.M.AljaboryA.M.AbbasH.M.GhanimM.RasheedJ.I.Effectiveness of Ivermectin as add-on Therapy in COVID-19 Management (Pilot Trial)medRxiv2020.2007.2007.20145979202010.1101/2020.07.07.20145979Search in Google Scholar
Grein J., Flanigan T. et al.: Compassionate Use of Remdesivir for Patients with Severe Covid-19. N. Engl. J. Med. 382, 2327–2336 (2020)GreinJ.FlaniganT.Compassionate Use of Remdesivir for Patients with Severe Covid-19N. Engl. J. Med.38223272336202010.1056/NEJMoa2007016716947632275812Search in Google Scholar
Gu H., Yang P. et al.: Angiotensin-converting enzyme 2 inhibits lung injury induced by respiratory syncytial virus. Sci. Rep. 6, 19840 (2016)GuH.YangP.Angiotensin-converting enzyme 2 inhibits lung injury induced by respiratory syncytial virusSci. Rep.619840201610.1038/srep19840472839826813885Search in Google Scholar
Haagmans B.L., Osterhaus A.D.M.E. et al.: Pegylated interferon-alpha protects type 1 pneumocytes against SARS coronavirus infection in macaques. Nat. Med. 10, 290–293 (2004)HaagmansB.L.OsterhausA.D.M.E.Pegylated interferon-alpha protects type 1 pneumocytes against SARS coronavirus infection in macaquesNat. Med.10290293200410.1038/nm1001709598614981511Search in Google Scholar
Habib A.M.G., Ali M.A.E., Zouaoui B.R., Taha M.A.H., Mohammed B.S., Saquib N.: Clinical outcomes among hospital patients with Middle East respiratory syndrome coronavirus (MERS-CoV) infection. BMC Infect. Dis. 19, 870–870 (2019)HabibA.M.G.AliM.A.E.ZouaouiB.R.TahaM.A.H.MohammedB.S.SaquibN.Clinical outcomes among hospital patients with Middle East respiratory syndrome coronavirus (MERS-CoV) infectionBMC Infect. Dis.19870870201910.1186/s12879-019-4555-5680553231640578Search in Google Scholar
Harigai M., Genovese M.C. et al.: FRI0077 Hepatitis b virus reactivation in patients with rheumatoid arthritis treated with baricitinib: post-hoc analysis from clinical trials. Ann. Rheumatic Dis. 77 (2018)HarigaiM.GenoveseM.C.FRI0077 Hepatitis b virus reactivation in patients with rheumatoid arthritis treated with baricitinib: post-hoc analysis from clinical trialsAnn. Rheumatic Dis.77201810.1136/annrheumdis-2018-eular.1935Search in Google Scholar
Hartwell D., Jones J., Baxter L., Shepherd J.: Peginterferon alfa and ribavirin for chronic hepatitis C in patients eligible for shortened treatment, re-treatment or in HCV/HIV co-infection: a systematic review and economic evaluation. Health Technol. Assess. 17, i-xii, 1–210 (2011)HartwellD.JonesJ.BaxterL.ShepherdJ.Peginterferon alfa and ribavirin for chronic hepatitis C in patients eligible for shortened treatment, re-treatment or in HCV/HIV co-infection: a systematic review and economic evaluationHealth Technol. Assess.17ixii1–210201110.3310/hta15170478094221473834Search in Google Scholar
Haschke M., Schuster M., Poglitsch M., Loibner H., Salzberg M., Bruggisser M., Penninger J., Krähenbühl S.: Pharmacokinetics and pharmacodynamics of recombinant human angiotensin-converting enzyme 2 in healthy human subjects. Clin. Pharmacokinet. 52, 783–792 (2013)HaschkeM.SchusterM.PoglitschM.LoibnerH.SalzbergM.BruggisserM.PenningerJ.KrähenbühlS.Pharmacokinetics and pharmacodynamics of recombinant human angiotensin-converting enzyme 2 in healthy human subjectsClin. Pharmacokinet.52783792201310.1007/s40262-013-0072-723681967Search in Google Scholar
He R., Adonov A., Traykova-Adonova M., Cao J., Cutts T., Grudesky E., Deschambaul Y., Berry J., Drebot M., Li X.: Potent and selective inhibition of SARS coronavirus replication by aurintricarboxylic acid. Biochem. Biophys. Res. Commun. 320, 1199–1203 (2004)HeR.AdonovA.Traykova-AdonovaM.CaoJ.CuttsT.GrudeskyE.DeschambaulY.BerryJ.DrebotM.LiX.Potent and selective inhibition of SARS coronavirus replication by aurintricarboxylic acidBiochem. Biophys. Res. Commun.32011991203200410.1016/j.bbrc.2004.06.076711106615249217Search in Google Scholar
Hemnes A.R., West J. et al.: A potential therapeutic role for angiotensin-converting enzyme 2 in human pulmonary arterial hypertension. Europ. Respir. J. 51, 1702638 (2018)HemnesA.R.WestJ.A potential therapeutic role for angiotensin-converting enzyme 2 in human pulmonary arterial hypertensionEurop. Respir. J.511702638201810.1183/13993003.02638-2017661321629903860Search in Google Scholar
Hensley L.E., Fritz L.E., Jahrling P.B., Karp C.L., Huggins J.W., Geisbert T.W.: Interferon-beta 1a and SARS coronavirus replication. Emerg. Infect. Dis. 10, 317–319 (2004)HensleyL.E.FritzL.E.JahrlingP.B.KarpC.L.HugginsJ.W.GeisbertT.W.Interferon-beta 1a and SARS coronavirus replicationEmerg. Infect. Dis.10317319200410.3201/eid1002.030482332291915030704Search in Google Scholar
Hoffmann M., Pöhlmann S. et al.: SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 181, 271–280.e278 (2020)HoffmannM.PöhlmannS.SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease InhibitorCell181271280.e278202010.1016/j.cell.2020.02.052710262732142651Search in Google Scholar
Hoffmann M., Schroeder S., Kleine-Weber H., Müller M.A., Drosten C., Pöhlmann S.: Nafamostat Mesylate Blocks Activation of SARS-CoV-2: New Treatment Option for COVID-19. Antimicrob. Agents Chemother. 64, e00754–00720 (2020)HoffmannM.SchroederS.Kleine-WeberH.MüllerM.A.DrostenC.PöhlmannS.Nafamostat Mesylate Blocks Activation of SARS-CoV-2: New Treatment Option for COVID-19Antimicrob. Agents Chemother.64e0075400720202010.1128/AAC.00754-20726951532312781Search in Google Scholar
Horby P., Landry M. et al.: Effect of hydroxychloroquine in hospitalized patients with COVID-19: Preliminary results from a multi-centre, randomized, controlled trial. medRxiv, 2020.2007.2015.20151852 (2020)HorbyP.LandryM.Effect of hydroxychloroquine in hospitalized patients with COVID-19: Preliminary results from a multi-centre, randomized, controlled trialmedRxiv2020.2007.2015.20151852202010.1101/2020.07.15.20151852Search in Google Scholar
Huang F., Luo L. et al.: A review of therapeutic agents and Chinese herbal medicines against SARS-COV-2 (COVID-19). Pharmacol. Res. 104929 (2020)HuangF.LuoL.A review of therapeutic agents and Chinese herbal medicines against SARS-COV-2 (COVID-19)Pharmacol. Res.104929202010.1016/j.phrs.2020.104929723795332442720Search in Google Scholar
Huang Y.-Q., Chen Y.-K. et al.: No Statistically Apparent Difference in Antiviral Effectiveness Observed Among Ribavirin Plus Interferon-Alpha, Lopinavir/Ritonavir Plus Interferon-Alpha, and Ribavirin Plus Lopinavir/Ritonavir Plus Interferon-Alpha in Patients With Mild to Moderate Coronavirus Disease 2019: Results of a Randomized, Open-Labeled Prospective Study. Front. Pharmacol. 11, 1071–1071 (2020)HuangY.-Q.ChenY.-K.No Statistically Apparent Difference in Antiviral Effectiveness Observed Among Ribavirin Plus Interferon-Alpha, Lopinavir/Ritonavir Plus Interferon-Alpha, and Ribavirin Plus Lopinavir/Ritonavir Plus Interferon-Alpha in Patients With Mild to Moderate Coronavirus Disease 2019: Results of a Randomized, Open-Labeled Prospective StudyFront. Pharmacol.1110711071202010.3389/fphar.2020.01071737885032765274Search in Google Scholar
Hung I.F.-N., Yuen K.-Y. et al.: Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. Lancet, 395, 1695–1704 (2020)HungI.F.-N.YuenK.-Y.Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trialLancet39516951704202010.1016/S0140-6736(20)31042-4721150032401715Search in Google Scholar
Iwata-Yoshikawa N., Okamura T., Shimizu Y., Hasegawa H., Takeda M., Nagata N.: TMPRSS2 Contributes to Virus Spread and Immunopathology in the Airways of Murine Models after Coronavirus Infection. J. Vir. 93, e01815–01818 (2019)Iwata-YoshikawaN.OkamuraT.ShimizuY.HasegawaH.TakedaM.NagataN.TMPRSS2 Contributes to Virus Spread and Immunopathology in the Airways of Murine Models after Coronavirus InfectionJ. Vir.93e0181501818201910.1128/JVI.01815-18640145130626688Search in Google Scholar
Jacobs M., Thomson E.C. et al: Late Ebola virus relapse causing meningoencephalitis: a case report. Lancet, 388, 498–503 (2016)JacobsM.ThomsonE.C.Late Ebola virus relapse causing meningoencephalitis: a case reportLancet388498503201610.1016/S0140-6736(16)30386-5496771527209148Search in Google Scholar
Jin X., Guo D. et al.: Characterization of the guanine-N7 methyltransferase activity of coronavirus nsp14 on nucleotide GTP. Virus Res. 176, 45–52 (2013)JinX.GuoD.Characterization of the guanine-N7 methyltransferase activity of coronavirus nsp14 on nucleotide GTPVirus Res.1764552201310.1016/j.virusres.2013.05.001711446623702198Search in Google Scholar
Jin Y.-H., Wang X.-H. et al.: A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version). Mil. Med. Res. 7, 4 (2020)JinY.-H.WangX.-H.A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version)Mil. Med. Res.74202010.1186/s40779-020-0233-6700334132029004Search in Google Scholar
Jomah S., Asdaq S.M.B., Al-Yamani M.J.: Clinical efficacy of antivirals against novel coronavirus (COVID-19): A review. J. Infect. Public Health, 9, 1187–1195 (2020)JomahS.AsdaqS.M.B.Al-YamaniM.J.Clinical efficacy of antivirals against novel coronavirus (COVID-19): A reviewJ. Infect. Public Health911871195202010.1016/j.jiph.2020.07.013739696132773212Search in Google Scholar
Joumaa H., Regard L., Carlier N., Chassagnon G., Alabadan E., Canouï E., L’Honneur A., Rozenberg F., Burgel P.R., Roche N.: A severe COVID-19 despite ongoing treatment with Lopinavir-Ritonavir. Respi. Med. Res. 78, 100780 (2020)JoumaaH.RegardL.CarlierN.ChassagnonG.AlabadanE.CanouïE.L’HonneurA.RozenbergF.BurgelP.R.RocheN.A severe COVID-19 despite ongoing treatment with Lopinavir-RitonavirRespi. Med. Res.78100780202010.1016/j.resmer.2020.100780736279032759053Search in Google Scholar
Karres I., Kremer J.P., Dietl I., Steckholzer U., Jochum M., Ertel W.: Chloroquine inhibits proinflammatory cytokine release into human whole blood. Am. J. Physiol. 274, R1058–1064 (1998)KarresI.KremerJ.P.DietlI.SteckholzerU.JochumM.ErtelW.Chloroquine inhibits proinflammatory cytokine release into human whole bloodAm. J. Physiol.274R10581064199810.1152/ajpregu.1998.274.4.R10589575969Search in Google Scholar
Kawase M., Shirato K., van der Hoek L., Taguchi F., Matsuyama S.: Simultaneous treatment of human bronchial epithelial cells with serine and cysteine protease inhibitors prevents severe acute respiratory syndrome coronavirus entry. J. Vir. 86, 6537–6545 (2012)KawaseM.ShiratoK.van der HoekL.TaguchiF.MatsuyamaS.Simultaneous treatment of human bronchial epithelial cells with serine and cysteine protease inhibitors prevents severe acute respiratory syndrome coronavirus entryJ. Vir.8665376545201210.1128/JVI.00094-12339353522496216Search in Google Scholar
Khalili J., Zhu H., Mak A., Yan Y., Zhu Y.: Novel coronavirus treatment with ribavirin: Groundwork for evaluation concerning COVID-19. J. Med. Vir. (2020)KhaliliJ.ZhuH.MakA.YanY.ZhuY.Novel coronavirus treatment with ribavirin: Groundwork for evaluation concerning COVID-19J. Med. Vir.202010.1002/jmv.25798722840832227493Search in Google Scholar
Khambholja K., Asudani D.: Potential repurposing of Favipiravir in COVID-19 outbreak based on current evidence. Travel Med. Infecti. Dis. 35, 101710 (2020)KhambholjaK.AsudaniD.Potential repurposing of Favipiravir in COVID-19 outbreak based on current evidenceTravel Med. Infecti. Dis.35101710202010.1016/j.tmaid.2020.101710725208432360327Search in Google Scholar
Khamitov R.A., Loginova S., Shchukina V.N., Borisevich S.V., Maksimov V.A., Shuster A.M.: Antiviral activity of arbidol and its derivatives against the pathogen of severe acute respiratory syndrome in the cell cultures. Vopr. Virusol. 53, 9–13 (2008)KhamitovR.A.LoginovaS.ShchukinaV.N.BorisevichS.V.MaksimovV.A.ShusterA.M.Antiviral activity of arbidol and its derivatives against the pathogen of severe acute respiratory syndrome in the cell culturesVopr. Virusol.539132008Search in Google Scholar
Khan R.J., Jha R.K., Amera G.M., Jain M., Singh E., Pathak A., Singh R.P., Muthukumaran J., Singh A.K.: Targeting SARS-CoV-2: a systematic drug repurposing approach to identify promising inhibitors against 3C-like proteinase and 2′-O-ribose methyltransferase. J. Biomol. Struct. Dyn. 0, 1–14 (2020)KhanR.J.JhaR.K.AmeraG.M.JainM.SinghE.PathakA.SinghR.P.MuthukumaranJ.SinghA.K.Targeting SARS-CoV-2: a systematic drug repurposing approach to identify promising inhibitors against 3C-like proteinase and 2′-O-ribose methyltransferaseJ. Biomol. Struct. Dyn.0114202010.1080/07391102.2020.1753577718941232266873Search in Google Scholar
Ko G.M., Reddy A.S., Kumar S., Bailey B.A., Garg R.: Computational analysis of HIV-1 protease protein binding pockets. J. Chem. Inform. Model. 50, 1759–1771 (2010)KoG.M.ReddyA.S.KumarS.BaileyB.A.GargR.Computational analysis of HIV-1 protease protein binding pocketsJ. Chem. Inform. Model.5017591771201010.1021/ci100200u298160820925403Search in Google Scholar
Kobayashi T., Nakatsuka K., Shimizu M., Tamura H., Shinya E., Atsukawa M., Harimoto H., Takahashi H., Sakamoto C.: Ribavirin modulates the conversion of human CD4(+) CD25(–) T cell to CD4(+) CD25(+) FOXP3(+) T cell via suppressing interleukin-10-producing regulatory T cell. Immunol. 137, 259–270 (2012)KobayashiT.NakatsukaK.ShimizuM.TamuraH.ShinyaE.AtsukawaM.HarimotoH.TakahashiH.SakamotoC.Ribavirin modulates the conversion of human CD4(+) CD25(–) T cell to CD4(+) CD25(+) FOXP3(+) T cell via suppressing interleukin-10-producing regulatory T cellImmunol.137259270201210.1111/imm.12005348268322891772Search in Google Scholar
Kong Y., Cai C., Ling L., Zeng L., Wu M., Wu Y., Zhang W., Liu Z.: Successful treatment of a centenarian with coronavirus disease 2019 (COVID-19) using convalescent plasma. Transf. Apheres. Sci. 102820 (2020)KongY.CaiC.LingL.ZengL.WuM.WuY.ZhangW.LiuZ.Successful treatment of a centenarian with coronavirus disease 2019 (COVID-19) using convalescent plasmaTransf. Apheres. Sci.102820202010.1016/j.transci.2020.102820723978132467007Search in Google Scholar
Koren G., King S., Knowles S., Phillips E.: Ribavirin in the treatment of SARS: A new trick for an old drug? CMAJ, 168, 1289–1292 (2003)KorenG.KingS.KnowlesS.PhillipsE.Ribavirin in the treatment of SARS: A new trick for an old drug?CMAJ168128912922003Search in Google Scholar
Krilov L.: Safety issues related to the administration of ribavirin. Pediatr. Infec. Dis. J. 21, 479–481 (2002)KrilovL.Safety issues related to the administration of ribavirinPediatr. Infec. Dis. J.21479481200210.1097/00006454-200205000-0003712150196Search in Google Scholar
Kuznik A., Bencina M., Svajger U., Jeras M., Rozman B., Jerala R.: Mechanism of endosomal TLR inhibition by antimalarial drugs and imidazoquinolines. J. Immunol. 186, 4794–4804 (2011)KuznikA.BencinaM.SvajgerU.JerasM.RozmanB.JeralaR.Mechanism of endosomal TLR inhibition by antimalarial drugs and imidazoquinolinesJ. Immunol.18647944804201110.4049/jimmunol.100070221398612Search in Google Scholar
La Rosée F., La Rosée P. et al.: The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation. Leukemia, 34, 1805–1815 (2020)La RoséeF.La RoséeP.The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammationLeukemia3418051815202010.1038/s41375-020-0891-0728220632518419Search in Google Scholar
Laing R., Gillan V., Devaney E.: Ivermectin – Old Drug, New Tricks? Trends Parasitol. 33, 463–472 (2017)LaingR.GillanV.DevaneyE.Ivermectin – Old Drug, New Tricks?Trends Parasitol.33463472201710.1016/j.pt.2017.02.004544632628285851Search in Google Scholar
Lecronier M., Dres M. et al.: Comparison of hydroxychloroquine, lopinavir/ritonavir, and standard of care in critically ill patients with SARS-CoV-2 pneumonia: an opportunistic retrospective analysis. Crit. Care, 24, 418–418 (2020)LecronierM.DresM.Comparison of hydroxychloroquine, lopinavir/ritonavir, and standard of care in critically ill patients with SARS-CoV-2 pneumonia: an opportunistic retrospective analysisCrit. Care24418418202010.1186/s13054-020-03117-9735164532653015Search in Google Scholar
Lee C.: CRISPR/Cas9-Based Antiviral Strategy: Current Status and the Potential Challenge. Molecules, 24, 1349 (2019)LeeC.CRISPR/Cas9-Based Antiviral Strategy: Current Status and the Potential ChallengeMolecules241349201910.3390/molecules24071349648026030959782Search in Google Scholar
Lee J.Y., Kim Y.-J., Chung E.H., Kim D.-W., Jeong I., Kim Y., Yun M.-R., Kim S.S., Kim G., Joh J.-S.: The clinical and virological features of the first imported case causing MERS-CoV outbreak in South Korea, 2015. BMC Infect. Dis. 17, 498–498 (2017)LeeJ.Y.KimY.-J.ChungE.H.KimD.-W.JeongI.KimY.YunM.-R.KimS.S.KimG.JohJ.-S.The clinical and virological features of the first imported case causing MERS-CoV outbreak in South Korea, 2015BMC Infect. Dis.17498498201710.1186/s12879-017-2576-5551273628709419Search in Google Scholar
Lei C., Fu W., Qian K., Li T., Zhang S., Fu W., Ding M., Hu S.: Neutralization of SARS-CoV-2 spike pseudotyped virus by recombinant ACE2-Ig. Nat. Commun. 11, 2070 (2020)LeiC.FuW.QianK.LiT.ZhangS.FuW.DingM.HuS.Neutralization of SARS-CoV-2 spike pseudotyped virus by recombinant ACE2-IgNat. Commun.112070202010.1038/s41467-020-16048-4726535532332765Search in Google Scholar
Li W., Moore M.J., Vasilieva N., Sui J., Wong S.K., Berne M.A., Somasundaran M., Sullivan J.L., Luzuriaga K., Greenough T.C. et al: Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature, 426, 450–454 (2003)LiW.MooreM.J.VasilievaN.SuiJ.WongS.K.BerneM.A.SomasundaranM.SullivanJ.L.LuzuriagaK.GreenoughT.C.Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirusNature426450454200310.1038/nature02145709501614647384Search in Google Scholar
Li Y., Li L. et al.: An exploratory randomized controlled study on the efficacy and safety of lopinavir/ritonavir or arbidol treating adult patients hospitalized with mild/moderate COVID-19 (ELACOI). medRxiv, 2020.2003.2019.20038984 (2020)LiY.LiL.An exploratory randomized controlled study on the efficacy and safety of lopinavir/ritonavir or arbidol treating adult patients hospitalized with mild/moderate COVID-19 (ELACOI)medRxiv2020.2003.2019.20038984202010.1101/2020.03.19.20038984Search in Google Scholar
Lian N., Xie H., Lin S., Huang J., Zhao J., Lin Q.: Umifenovir treatment is not associated with improved outcomes in patients with coronavirus disease 2019: a retrospective study. Clin. Microbiol. Infect. 26, 917–921 (2020)LianN.XieH.LinS.HuangJ.ZhaoJ.LinQ.Umifenovir treatment is not associated with improved outcomes in patients with coronavirus disease 2019: a retrospective studyClin. Microbiol. Infect.26917921202010.1016/j.cmi.2020.04.026718275032344167Search in Google Scholar
Lin S., Shen R., He J., Li X., Guo X.: Molecular modeling evaluation of the binding effect of ritonavir, lopinavir and darunavir to severe acute respiratory syndrome Coronavirus 2 proteases. bioRxiv, 2020.2001.2031.929695 (2020)LinS.ShenR.HeJ.LiX.GuoX.Molecular modeling evaluation of the binding effect of ritonavir, lopinavir and darunavir to severe acute respiratory syndrome Coronavirus 2 proteasesbioRxiv2020.2001.2031.929695202010.1101/2020.01.31.929695Search in Google Scholar
Liu Q., Peng P. et al.: The effect of Arbidol Hydrochloride on reducing mortality of Covid-19 patients: a retrospective study of real world date from three hospitals in Wuhan. medRxiv, 2020.2004.2011.20056523 (2020)LiuQ.PengP.The effect of Arbidol Hydrochloride on reducing mortality of Covid-19 patients: a retrospective study of real world date from three hospitals in WuhanmedRxiv2020.2004.2011.200565232020Search in Google Scholar
Liu S., Lien C.Z., Selvaraj P., Wang T.T.: Evaluation of 19 antiviral drugs against SARS-CoV-2 Infection. bioRxiv, 2020.2004. 2029.067983 (2020)LiuS.LienC.Z.SelvarajP.WangT.T.Evaluation of 19 antiviral drugs against SARS-CoV-2 InfectionbioRxiv2020.2004. 2029.067983202010.1101/2020.04.29.067983Search in Google Scholar
Lou Y., Liu L., Qiu Y.: Clinical outcomes and plasma concentrations of baloxavir marboxil and favipiravir in COVID-19 patients: an exploratory randomized, controlled trial. medRxiv, 2020.2004.2029.20085761 (2020)LouY.LiuL.QiuY.Clinical outcomes and plasma concentrations of baloxavir marboxil and favipiravir in COVID-19 patients: an exploratory randomized, controlled trialmedRxiv2020.2004.2029.20085761202010.1016/j.ejps.2020.105631758571933115675Search in Google Scholar
Loutfy M.R., Fish E. N. et al.: Interferon Alfacon-1 Plus Corticosteroids in Severe Acute Respiratory Syndrome A Preliminary Study. JAMA, 290, 3222–3228 (2003)LoutfyM.R.FishE. N.Interferon Alfacon-1 Plus Corticosteroids in Severe Acute Respiratory Syndrome A Preliminary StudyJAMA29032223228200310.1001/jama.290.24.322214693875Search in Google Scholar
Lu H., Stratton C.W., Tang Y.-W.: Outbreak of pneumonia of unknown etiology in Wuhan, China: The mystery and the miracle. J. Med. Vir. 92, 401–402 (2020)LuH.StrattonC.W.TangY.-W.Outbreak of pneumonia of unknown etiology in Wuhan, China: The mystery and the miracleJ. Med. Vir.92401402202010.1002/jmv.25678716662831950516Search in Google Scholar
Lucas J.M., Nelson P.S. et al.: The androgen-regulated protease TMPRSS2 activates a proteolytic cascade involving components of the tumor microenvironment and promotes prostate cancer metastasis. Cancer Discov. 4, 1310–1325 (2014)LucasJ.M.NelsonP.S.The androgen-regulated protease TMPRSS2 activates a proteolytic cascade involving components of the tumor microenvironment and promotes prostate cancer metastasisCancer Discov.413101325201410.1158/2159-8290.CD-13-1010440978625122198Search in Google Scholar
Luo P., Liu Y., Qiu L., Liu X., Liu D., Li J.: Tocilizumab treatment in COVID-19: A single center experience. J. Med. Virol. 92, 814–818 (2020)LuoP.LiuY.QiuL.LiuX.LiuD.LiJ.Tocilizumab treatment in COVID-19: A single center experienceJ. Med. Virol.92814818202010.1002/jmv.25801726212532253759Search in Google Scholar
Kowalik M.M., Trzonkowski P., Łasińska-Kowara M., Mital A., Smiatacz T., Jaguszewski M.: COVID-19 – Toward a comprehensive understanding of the disease. Cardiol. J. 27, 99–114 (2020)KowalikM.M.TrzonkowskiP.Łasińska-KowaraM.MitalA.SmiataczT.JaguszewskiM.COVID-19 – Toward a comprehensive understanding of the diseaseCardiol. J.2799114202010.5603/CJ.a2020.0065801603032378729Search in Google Scholar
Madrid P.B., Tanga J. et al.: Evaluation of Ebola Virus Inhibitors for Drug Repurposing. ACS Infect. Dis. 1, 317–326 (2015)MadridP.B.TangaJ.Evaluation of Ebola Virus Inhibitors for Drug RepurposingACS Infect. Dis.1317326201510.1021/acsinfecdis.5b0003027622822Search in Google Scholar
Maggio R., Corsini G.U.: Repurposing the mucolytic cough suppressant and TMPRSS2 protease inhibitor bromhexine for the prevention and management of SARS-CoV-2 infection. Pharmacolog. Res. 104837 (2020)MaggioR.CorsiniG.U.Repurposing the mucolytic cough suppressant and TMPRSS2 protease inhibitor bromhexine for the prevention and management of SARS-CoV-2 infectionPharmacolog. Res.104837202010.1016/j.phrs.2020.104837717591132334052Search in Google Scholar
Mahévas M., Costedoat-Chalumeau N. et al: Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen: observational comparative study using routine care data. BMJ, 369, m1844 (2020)MahévasM.Costedoat-ChalumeauN.Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen: observational comparative study using routine care dataBMJ369m1844202010.1136/bmj.m1844722147232409486Search in Google Scholar
Mair-Jenkins J., Beck C.R. et al.: The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis. J. Infect. Dis. 211, 80–90 (2015)Mair-JenkinsJ.BeckC.R.The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysisJ. Infect. Dis.2118090201510.1093/infdis/jiu396426459025030060Search in Google Scholar
Matsuyama S., Takeda M. et al.: Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells. Proc. Nat. Acad. Sci. USA, 117, 7001 (2020)MatsuyamaS.TakedaM.Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cellsProc. Nat. Acad. Sci. USA1177001202010.1073/pnas.2002589117713213032165541Search in Google Scholar
McAuliffe J., Subbarao K. et al.: Replication of SARS coronavirus administered into the respiratory tract of African Green, rhesus and cynomolgus monkeys. Virology, 330, 8–15 (2004)McAuliffeJ.SubbaraoK.Replication of SARS coronavirus administered into the respiratory tract of African Green, rhesus and cynomolgus monkeysVirology330815200410.1016/j.virol.2004.09.030711180815527829Search in Google Scholar
Mehra M.R., Desai S.S., Ruschitzka F., Patel A.N.: Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis. Lancet, RETRACTED (2020)MehraM.R.DesaiS.S.RuschitzkaF.PatelA.N.Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysisLancetRETRACTED202010.1016/S0140-6736(20)31180-6725529332450107Search in Google Scholar
Mehta P., McAuley D.F., Brown M., Sanchez E., Tattersall R.S., Manson J.J.: COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet, 395, 1033–1034 (2020)MehtaP.McAuleyD.F.BrownM.SanchezE.TattersallR.S.MansonJ.J.COVID-19: consider cytokine storm syndromes and immunosuppressionLancet39510331034202010.1016/S0140-6736(20)30628-0727004532192578Search in Google Scholar
Minato T., Kuba K. et al.: B38-CAP is a bacteria-derived ACE2-like enzyme that suppresses hypertension and cardiac dysfunction. Nat. Commun. 11, 1058–1058 (2020)MinatoT.KubaK.B38-CAP is a bacteria-derived ACE2-like enzyme that suppresses hypertension and cardiac dysfunctionNat. Commun.1110581058202010.1038/s41467-020-14867-z704419632103002Search in Google Scholar
Miyamoto Y., Yamada K., Yoneda Y.: Importin α: a key molecule in nuclear transport and non-transport functions. J. Biochem. 160, 69–75 (2016)MiyamotoY.YamadaK.YonedaY.Importin α: a key molecule in nuclear transport and non-transport functionsJ. Biochem.1606975201610.1093/jb/mvw03627289017Search in Google Scholar
Mo Y., Fisher D.: A review of treatment modalities for Middle East Respiratory Syndrome. J. Antimicrob. Chemother. 71, 3340–3350 (2016)MoY.FisherD.A review of treatment modalities for Middle East Respiratory SyndromeJ. Antimicrob. Chemother.7133403350201610.1093/jac/dkw338710976027585965Search in Google Scholar
Molina J.M., Delaugerre C., Le Goff J., Mela-Lima B., Ponscarme D., Goldwirt L., de Castro N.: No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection. Méd. Mal. Infect. 50, 384 (2020)MolinaJ.M.DelaugerreC.Le GoffJ.Mela-LimaB.PonscarmeD.GoldwirtL.de CastroN.No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infectionMéd. Mal. Infect.50384202010.1016/j.medmal.2020.03.006719536932240719Search in Google Scholar
Monteil V., Penninger J.M. et al.: Inhibition of SARS-CoV-2 Infections in Engineered Human Tissues Using Clinical-Grade Soluble Human ACE2. Cell, 181, 905–913.e7 (2020)MonteilV.PenningerJ.M.Inhibition of SARS-CoV-2 Infections in Engineered Human Tissues Using Clinical-Grade Soluble Human ACE2Cell181905913.e7202010.1016/j.cell.2020.04.004718199832333836Search in Google Scholar
Navarro G., Taroumian S., Barroso N., Duan L., Furst D.: Tocilizumab in rheumatoid arthritis: a meta-analysis of efficacy and selected clinical conundrums. Semin. Arthritis Rheum. 43, 458–469 (2014)NavarroG.TaroumianS.BarrosoN.DuanL.FurstD.Tocilizumab in rheumatoid arthritis: a meta-analysis of efficacy and selected clinical conundrumsSemin. Arthritis Rheum.43458469201410.1016/j.semarthrit.2013.08.00124262929Search in Google Scholar
Nutho B., Mahalapbutr P., Hengphasatporn K., Pattaranggoon N.C., Simanon N., Shigeta Y., Hannongbua S., Rungrotmongkol T.: Why are lopinavir and ritonavir effective against the newly emerged coronavirus 2019? atomistic insights into the inhibitory mechanisms. Biochemistry, (2020)NuthoB.MahalapbutrP.HengphasatpornK.PattaranggoonN.C.SimanonN.ShigetaY.HannongbuaS.RungrotmongkolT.Why are lopinavir and ritonavir effective against the newly emerged coronavirus 2019? atomistic insights into the inhibitory mechanismsBiochemistry202010.1021/acs.biochem.0c00160718487832293875Search in Google Scholar
Nyström K., Waldenström J., Tang K.-W., Lagging M.: Ribavirin: pharmacology, multiple modes of action and possible future perspectives. Fut. Virol. 14, 153–160 (2019)NyströmK.WaldenströmJ.TangK.-W.LaggingM.Ribavirin: pharmacology, multiple modes of action and possible future perspectivesFut. Virol.14153160201910.2217/fvl-2018-0166Search in Google Scholar
Omrani A.S., Saad M.M., Baig K., Bahloul A., Abdul-Matin M., Alaidaroos A.Y., Almakhlafi G.A., Albarrak M.M., Memish Z.A., Albarrak A.M.: Ribavirin and interferon alfa-2a for severe Middle East respiratory syndrome coronavirus infection: a retrospective cohort study. Lancet Infect. Dis. 14, 1090–1095 (2014)OmraniA.S.SaadM.M.BaigK.BahloulA.Abdul-MatinM.AlaidaroosA.Y.AlmakhlafiG.A.AlbarrakM.M.MemishZ.A.AlbarrakA.M.Ribavirin and interferon alfa-2a for severe Middle East respiratory syndrome coronavirus infection: a retrospective cohort studyLancet Infect. Dis.1410901095201410.1016/S1473-3099(14)70920-X710635725278221Search in Google Scholar
Ou X., Qian Z. et al.: Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV. Nat. Commun. 11, 1620 (2020)OuX.QianZ.Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoVNat. Commun.111620202010.1038/s41467-020-15562-9710051532221306Search in Google Scholar
Padhi A., Seal A., Tripathi T.: How does Arbidol Inhibit the Novel Coronavirus SARS-CoV-2? Atomistic Insights from Molecular Dynamics Simulations; ChemRxiv, PREPRINT (2020)PadhiA.SealA.TripathiT.How does Arbidol Inhibit the Novel Coronavirus SARS-CoV-2? Atomistic Insights from Molecular Dynamics SimulationsChemRxivPREPRINT202010.26434/chemrxiv.12464576.v1Search in Google Scholar
Patrizia A., Pierluigi B., Vincenzo d.A., Giustina D.S., Luca M., Angelo O.: Position paper on the preparation of immune plasma to be used in the treatment of patients with COVID-19. Transfus. Apher. Sci. 59, 102817 (2020)PatriziaA.PierluigiB.Vincenzod.A.GiustinaD.S.LucaM.AngeloO.Position paper on the preparation of immune plasma to be used in the treatment of patients with COVID-19Transfus. Apher. Sci.59102817202010.1016/j.transci.2020.102817723977532532691Search in Google Scholar
Peng F., Tu L., Yang Y., Hu P., Wang R., Hu Q., Cao F., Jiang T., Sun J., Xu G. et al: Management and Treatment of COVID-19: The Chinese Experience. Can. J. Cardiol. 36, 915–930 (2020)PengF.TuL.YangY.HuP.WangR.HuQ.CaoF.JiangT.SunJ.XuG.Management and Treatment of COVID-19: The Chinese ExperienceCan. J. Cardiol.36915930202010.1016/j.cjca.2020.04.010716277332439306Search in Google Scholar
Pilkington V., Pepperrell T., Hill A.: A review of the safety of favipiravir – a potential treatment in the COVID-19 pandemic? J. Virus Erad. 6, 45–51 (2020)PilkingtonV.PepperrellT.HillA.A review of the safety of favipiravir – a potential treatment in the COVID-19 pandemic?J. Virus Erad.64551202010.1016/S2055-6640(20)30016-9733150632405421Search in Google Scholar
Praveen D., Puvvada R.C., M V.A.: Janus kinase inhibitor baricitinib is not an ideal option for management of COVID-19. Int. J. Antimicrob. Agents, 55, 105967–105967 (2020)PraveenD.PuvvadaR.C.MV.A.Janus kinase inhibitor baricitinib is not an ideal option for management of COVID-19Int. J. Antimicrob. Agents55105967105967202010.1016/j.ijantimicag.2020.105967712860032259575Search in Google Scholar
Qaseem A., Yost J., Etxeandia-Ikobaltzeta I., Miller M.C., Abraham G.M., Obley A.J., Forciea M.A., Jokela J.A., Humphrey L.L.: Should clinicians use chloroquine or hydroxychloroquine alone or in combination with azithromycin for the prophylaxis or treatment of COVID-19? Living practice points from the american college of physicians (Version 1). Ann. Intern. Medi. 173, 137–142 (2020)QaseemA.YostJ.Etxeandia-IkobaltzetaI.MillerM.C.AbrahamG.M.ObleyA.J.ForcieaM.A.JokelaJ.A.HumphreyL.L.Should clinicians use chloroquine or hydroxychloroquine alone or in combination with azithromycin for the prophylaxis or treatment of COVID-19? Living practice points from the american college of physicians (Version 1)Ann. Intern. Medi.173137142202010.7326/M20-1998728171532422063Search in Google Scholar
Radbel J., Narayanan N., Bhatt P.J.: Use of Tocilizumab for COVID-19-Induced Cytokine Release Syndrome: A Cautionary Case Report. Chest, 158, e15–e19 (2020)RadbelJ.NarayananN.BhattP.J.Use of Tocilizumab for COVID-19-Induced Cytokine Release Syndrome: A Cautionary Case ReportChest158e15e19202010.1016/j.chest.2020.04.024719507032343968Search in Google Scholar
Raimondo M.G., Biggioggero M., Crotti C., Becciolini A., Favalli E.G.: Profile of sarilumab and its potential in the treatment of rheumatoid arthritis. Drug Des. Devel. Ther. 11, 1593–1603 (2017)RaimondoM.G.BiggioggeroM.CrottiC.BeccioliniA.FavalliE.G.Profile of sarilumab and its potential in the treatment of rheumatoid arthritisDrug Des. Devel. Ther.1115931603201710.2147/DDDT.S100302544769928579757Search in Google Scholar
Ramanathan A., Robb G.B., Chan S.-H.: mRNA capping: biological functions and applications. Nucleic Acids Res. 44, 7511–7526 (2016)RamanathanA.RobbG.B.ChanS.-H.mRNA capping: biological functions and applicationsNucleic Acids Res.4475117526201610.1093/nar/gkw551502749927317694Search in Google Scholar
Randall R., Goodbourn S.: Interferons and viruses: An interplay between induction, signalling, antiviral responses and virus countermeasures. J. Gen. Virol. 89, 1–47 (2008)RandallR.GoodbournS.Interferons and viruses: An interplay between induction, signalling, antiviral responses and virus countermeasuresJ. Gen. Virol.89147200810.1099/vir.0.83391-018089727Search in Google Scholar
Rattanaumpawan P., Jirajariyavej S., Lerdlamyong K., Palavutitotai N., Saiyarin J.: Real-world experience with favipiravir for treatment of COVID-19 in Thailand: Results from a multi-center observational study. medRxiv, 2020.2006.2024.20133249 (2020)RattanaumpawanP.JirajariyavejS.LerdlamyongK.PalavutitotaiN.SaiyarinJ.Real-world experience with favipiravir for treatment of COVID-19 in Thailand: Results from a multi-center observational studymedRxiv2020.2006.2024.20133249202010.1101/2020.06.24.20133249Search in Google Scholar
Retallack H., DeRisi J.L. et al.: Zika virus cell tropism in the developing human brain and inhibition by azithromycin. Proc. Nat. Acad. Sci. USA, 113, 14408 (2016)RetallackH.DeRisiJ.L.Zika virus cell tropism in the developing human brain and inhibition by azithromycinProc. Nat. Acad. Sci. USA11314408201610.1073/pnas.1618029113516716927911847Search in Google Scholar
Richardson P., Griffin I., Tucker C., Smith D., Oechsle O., Phelan A., Stebbing J.: Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. Lancet, 395, e30–e31 (2020)RichardsonP.GriffinI.TuckerC.SmithD.OechsleO.PhelanA.StebbingJ.Baricitinib as potential treatment for 2019-nCoV acute respiratory diseaseLancet395e30e31202010.1016/S0140-6736(20)30304-4713798532032529Search in Google Scholar
Rijckborst V., Janssen H.L.A.: The Role of Interferon in Hepatitis B Therapy. Curr. Hepat. Rep. 9, 231–238 (2010)RijckborstV.JanssenH.L.A.The Role of Interferon in Hepatitis B TherapyCurr. Hepat. Rep.9231238201010.1007/s11901-010-0055-1294546620949114Search in Google Scholar
Rolain J.-M., Colson P., Raoult D.: Recycling of chloroquine and its hydroxyl analogue to face bacterial, fungal and viral infections in the 21st century. Int. J. Antimicrob. Agents, 30, 297–308 (2007)RolainJ.-M.ColsonP.RaoultD.Recycling of chloroquine and its hydroxyl analogue to face bacterial, fungal and viral infections in the 21st centuryInt. J. Antimicrob. Agents30297308200710.1016/j.ijantimicag.2007.05.015712684717629679Search in Google Scholar
Sallard E., Lescure F.-X., Yazdanpanah Y., Mentre F., Peiffer-Smadja N.: Type 1 interferons as a potential treatment against COVID-19. Antiviral Res. 178, 104791–104791 (2020)SallardE.LescureF.-X.YazdanpanahY.MentreF.Peiffer-SmadjaN.Type 1 interferons as a potential treatment against COVID-19Antiviral Res.178104791104791202010.1016/j.antiviral.2020.104791713838232275914Search in Google Scholar
Savarino A., Boelaert J.R., Cassone A., Majori G., Cauda R.: Effects of chloroquine on viral infections: an old drug against today’s diseases? Lancet Infect. Dis. 3, 722–727 (2003)SavarinoA.BoelaertJ.R.CassoneA.MajoriG.CaudaR.Effects of chloroquine on viral infections: an old drug against today’s diseases?Lancet Infect. Dis.3722727200310.1016/S1473-3099(03)00806-5Search in Google Scholar
Shalhoub S., Farahat F., Al-Jiffri A., Simhairi R., Shamma O., Siddiqi N., Mushtaq A.: IFN-α2a or IFN-β1a in combination with ribavirin to treat Middle East respiratory syndrome coronavirus pneumonia: a retrospective study. J. Antimicrob. Chemother. 70, 2129–2132 (2015)ShalhoubS.FarahatF.Al-JiffriA.SimhairiR.ShammaO.SiddiqiN.MushtaqA.IFN-α2a or IFN-β1a in combination with ribavirin to treat Middle East respiratory syndrome coronavirus pneumonia: a retrospective studyJ. Antimicrob. Chemother.7021292132201510.1093/jac/dkv085720242925900158Search in Google Scholar
Sharma A.: Chloroquine Paradox May Cause More Damage Than Help Fight COVID-19. Microbes Infect. 22, 154–156 (2020)SharmaA.Chloroquine Paradox May Cause More Damage Than Help Fight COVID-19Microbes Infect.22154156202010.1016/j.micinf.2020.04.004716274032305500Search in Google Scholar
Sheahan T.P., Baric R.S. et al.: Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat. Commun. 11, 222–222 (2020)SheahanT.P.BaricR.S.Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoVNat. Commun.11222222202010.1038/s41467-019-13940-6695430231924756Search in Google Scholar
Shen C., Liu L. et al.: Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma. JAMA, 323, 1582–1589 (2020)ShenC.LiuL.Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent PlasmaJAMA32315821589202010.1001/jama.2020.4783710150732219428Search in Google Scholar
Shen L.W., Mao H.J., Wu Y.L., Tanaka Y., Zhang W.: TMPRSS2: A potential target for treatment of influenza virus and coronavirus infections. Biochimie, 142, 1–10 (2017)ShenL.W.MaoH.J.WuY.L.TanakaY.ZhangW.TMPRSS2: A potential target for treatment of influenza virus and coronavirus infectionsBiochimie142110201710.1016/j.biochi.2017.07.016711690328778717Search in Google Scholar
Shi L., Xiong H., He J., Deng H., Li Q., Zhong Q., Hou W., Cheng L., Xiao H., Yang Z.: Antiviral activity of arbidol against influenza A virus, respiratory syncytial virus, rhinovirus, coxsackie virus and adenovirus in vitro and in vivo. Arch. Virol. 152, 1447–1455 (2007)ShiL.XiongH.HeJ.DengH.LiQ.ZhongQ.HouW.ChengL.XiaoH.YangZ.Antiviral activity of arbidol against influenza A virus, respiratory syncytial virus, rhinovirus, coxsackie virus and adenovirus in vitro and in vivoArch. Virol.15214471455200710.1007/s00705-007-0974-517497238Search in Google Scholar
Shirato K., Kawase M., Matsuyama S.: Wild-type human coronaviruses prefer cell-surface TMPRSS2 to endosomal cathepsins for cell entry. Virology, 517, 9–15 (2018)ShiratoK.KawaseM.MatsuyamaS.Wild-type human coronaviruses prefer cell-surface TMPRSS2 to endosomal cathepsins for cell entryVirology517915201810.1016/j.virol.2017.11.012711202929217279Search in Google Scholar
Sin J.H., Zangardi M.L.: Ruxolitinib for secondary hemophagocytic lymphohistiocytosis: First case report. Hematol. Oncol. Stem Cell Ther. 12, 166–170 (2019)SinJ.H.ZangardiM.L.Ruxolitinib for secondary hemophagocytic lymphohistiocytosis: First case reportHematol. Oncol. Stem Cell Ther.12166170201910.1016/j.hemonc.2017.07.00228834694Search in Google Scholar
Stebbing J., Corebellino M. et al.: Mechanism of baricitinib supports artificial intelligence-predicted testing in COVID-19 patients. EMBO Mol. Med. 12, e12697 (2020)StebbingJ.CorebellinoM.Mechanism of baricitinib supports artificial intelligence-predicted testing in COVID-19 patientsEMBO Mol. Med.12e12697202010.15252/emmm.202012697730065732473600Search in Google Scholar
Stebbing J., Phelan A., Griffin I., Tucker C., Oechsle O., Smith D., Richardson P.: COVID-19: combining antiviral and anti-inflammatory treatments. Lancet Infect. Dis. 20, 400–402 (2020)StebbingJ.PhelanA.GriffinI.TuckerC.OechsleO.SmithD.RichardsonP.COVID-19: combining antiviral and anti-inflammatory treatmentsLancet Infect. Dis.20400402202010.1016/S1473-3099(20)30132-8715890332113509Search in Google Scholar
Ströher U., DiCaro A., Li Y., Strong J.E., Aoki F., Plummer F., Jones S.M., Feldmann H.: Severe Acute Respiratory Syndrome-Related Coronavirus Is Inhibited by Interferon-α. J. Infect. Dis. 189, 1164–1167 (2004)StröherU.DiCaroA.LiY.StrongJ.E.AokiF.PlummerF.JonesS.M.FeldmannH.Severe Acute Respiratory Syndrome-Related Coronavirus Is Inhibited by Interferon-αJ. Infect. Dis.18911641167200410.1086/382597710964315031783Search in Google Scholar
Talukdar R., Tandon R.K.: Pancreatic stellate cells: New target in the treatment of chronic pancreatitis. J. Gastroenterol. Hepatol. 23, 34–41 (2008)TalukdarR.TandonR.K.Pancreatic stellate cells: New target in the treatment of chronic pancreatitisJ. Gastroenterol. Hepatol.233441200810.1111/j.1440-1746.2007.05206.x17995943Search in Google Scholar
Tam R.C., Pai B., Bard J., Lim C., Averett D.R., Phan U.T., Milovanovic T.: Ribavirin polarizes human T cell responses towards a Type 1 cytokine profile. J. Hepatol. 30, 376–382 (1999)TamR.C.PaiB.BardJ.LimC.AverettD.R.PhanU.T.MilovanovicT.Ribavirin polarizes human T cell responses towards a Type 1 cytokine profileJ. Hepatol.30376382199910.1016/S0168-8278(99)80093-2Search in Google Scholar
Tang W., Xie Q. et al.: Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial. BMJ, 369, m1849 (2020)TangW.XieQ.Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trialBMJ369m1849202010.1136/bmj.m1849722147332409561Search in Google Scholar
Timani K.A., Zhu Y. et al.: Nuclear/nucleolar localization properties of C-terminal nucleocapsid protein of SARS coronavirus. Virus Res. 114, 23–34 (2005)TimaniK.A.ZhuY.Nuclear/nucleolar localization properties of C-terminal nucleocapsid protein of SARS coronavirusVirus Res.1142334200510.1016/j.virusres.2005.05.007711409515992957Search in Google Scholar
Tipnis S., Hooper N., Hyde R., Karran E.H., Christie G., Turner A.J.: A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase. J. Biol. Chem. 275, 33238–33243 (2000)TipnisS.HooperN.HydeR.KarranE.H.ChristieG.TurnerA.J.A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidaseJ. Biol. Chem.2753323833243200010.1074/jbc.M00261520010924499Search in Google Scholar
Tong S., Su Y., Yu Y., Wu C., Chen J., Wang S., Jiang J.: Ribavirin therapy for severe COVID-19: a retrospective cohort study. Int. J. Antimicrob. Agents, 56, 106114–106114 (2020)TongS.SuY.YuY.WuC.ChenJ.WangS.JiangJ.Ribavirin therapy for severe COVID-19: a retrospective cohort studyInt. J. Antimicrob. Agents56106114106114202010.1016/j.ijantimicag.2020.106114737777232712334Search in Google Scholar
Treml B., Loeckinger A. et al.: Recombinant angiotensin-converting enzyme 2 improves pulmonary blood flow and oxygenation in lipopolysaccharide-induced lung injury in piglets. Crit. Care Med. 38, 596–601 (2010)TremlB.LoeckingerA.Recombinant angiotensin-converting enzyme 2 improves pulmonary blood flow and oxygenation in lipopolysaccharide-induced lung injury in pigletsCrit. Care Med.38596601201010.1097/CCM.0b013e3181c0300919851091Search in Google Scholar
Tu Y.-F., Chien C.-S., Yarmishyn A., Lin Y.-Y., Luo Y.-H., Lin Y.-T., Lai W.-Y., Yang D.-M., Chou S.-J., Yang Y.-P. et al.: A Review of SARS-CoV-2 and the ongoing clinical trials. Int. J. Mol. Sci. 21, 2657 (2020)TuY.-F.ChienC.-S.YarmishynA.LinY.-Y.LuoY.-H.LinY.-T.LaiW.-Y.YangD.-M.ChouS.-J.YangY.-P.A Review of SARS-CoV-2 and the ongoing clinical trialsInt. J. Mol. Sci.212657202010.3390/ijms21072657717789832290293Search in Google Scholar
Ujike M., Nishikawa H., Otaka A., Yamamoto N., Yamamoto N., Matsuoka M., Kodama E., Fujii N., Taguchi F.: Heptad repeat-derived peptides block protease-mediated direct entry from the cell surface of severe acute respiratory syndrome coronavirus but not entry via the endosomal pathway. J. Virol. 82, 588 (2008)UjikeM.NishikawaH.OtakaA.YamamotoN.YamamotoN.MatsuokaM.KodamaE.FujiiN.TaguchiF.Heptad repeat-derived peptides block protease-mediated direct entry from the cell surface of severe acute respiratory syndrome coronavirus but not entry via the endosomal pathwayJ. Virol.82588200810.1128/JVI.01697-07222440017942557Search in Google Scholar
Uno Y.: Camostat mesilate therapy for COVID-19. Intern. Emerg. Med. 1–2 (2020)UnoY.Camostat mesilate therapy for COVID-19Intern. Emerg. Med.12202010.1007/s11739-020-02345-9718852032347443Search in Google Scholar
van Kraaij T.D.A., Mostard R.L., Ramiro S., Magro Checa C., van Dongen C.M., van Haren E.H., Buijs J., Landewé R.B.: Tocilizumab in Severe COVID-19 Pneumonia and Concomitant Cytokine Release Syndrome. Eur. J. Case Rep. Int. Med. 7, 001675–001675 (2020)van KraaijT.D.A.MostardR.L.RamiroS.Magro ChecaC.van DongenC.M.van HarenE.H.BuijsJ.LandewéR.B.Tocilizumab in Severe COVID-19 Pneumonia and Concomitant Cytokine Release SyndromeEur. J. Case Rep. Int. Med.7001675001675202010.12890/2020_001675721382432399455Search in Google Scholar
van Rhee F., Kurzrock R. et al.: Siltuximab, a novel anti-interleukin-6 monoclonal antibody, for Castleman’s disease. J. Clin. Oncol. 28, 3701–3708 (2010)van RheeF.KurzrockR.Siltuximab, a novel anti-interleukin-6 monoclonal antibody, for Castleman’s diseaseJ. Clin. Oncol.2837013708201010.1200/JCO.2009.27.237720625121Search in Google Scholar
Vincent M.J., Bergeron E., Benjannet S., Erickson B.R., Rollin P.E., Ksiazek T.G., Seidah N.G., Nichol S.T.: Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol. J. 2, 69–69 (2005)VincentM.J.BergeronE.BenjannetS.EricksonB.R.RollinP.E.KsiazekT.G.SeidahN.G.NicholS.T.Chloroquine is a potent inhibitor of SARS coronavirus infection and spreadVirol. J.26969200510.1186/1743-422X-2-69123286916115318Search in Google Scholar
Wagstaff K.M., Sivakumaran H., Heaton S.M., Harrich D., Jans D.A.: Ivermectin is a specific inhibitor of importin α/β-mediated nuclear import able to inhibit replication of HIV-1 and dengue virus. Biochem. J. 443, 851–856 (2012)WagstaffK.M.SivakumaranH.HeatonS.M.HarrichD.JansD.A.Ivermectin is a specific inhibitor of importin α/β-mediated nuclear import able to inhibit replication of HIV-1 and dengue virusBiochem. J.443851856201210.1042/BJ20120150332799922417684Search in Google Scholar
Wan S., Chen Y. et al.: Characteristics of lymphocyte subsets and cytokines in peripheral blood of 123 hospitalized patients with 2019 novel coronavirus pneumonia (NCP). medRxiv, 2020.2002.2010.20021832 (2020)WanS.ChenY.Characteristics of lymphocyte subsets and cytokines in peripheral blood of 123 hospitalized patients with 2019 novel coronavirus pneumonia (NCP)medRxiv2020.2002.2010.20021832202010.1101/2020.02.10.20021832Search in Google Scholar
Wang J., Wang Y., Wu L., Wang X., Jin Z., Gao Z., Wang Z.: Ruxolitinib for refractory/relapsed hemophagocytic lymphohistiocytosis. Haematologica, 105, e210–e212 (2019)WangJ.WangY.WuL.WangX.JinZ.GaoZ.WangZ.Ruxolitinib for refractory/relapsed hemophagocytic lymphohistiocytosisHaematologica105e210e212201910.3324/haematol.2019.222471719346231515353Search in Google Scholar
Wang M., Cao R., Zhang L., Yang X., Liu J., Xu M., Shi Z., Hu Z., Zhong W., Xiao G.: Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 30, 269–271 (2020)WangM.CaoR.ZhangL.YangX.LiuJ.XuM.ShiZ.HuZ.ZhongW.XiaoG.Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitroCell Res.30269271202010.1038/s41422-020-0282-0705440832020029Search in Google Scholar
Wang X., Cao R., Zhang H., Liu J., Xu M., Hu H., Li Y., Zhao L., Li W., Sun X. et al: The anti-influenza virus drug, arbidol is an efficient inhibitor of SARS-CoV-2 in vitro. Cell Discov. 6, 28 (2020)WangX.CaoR.ZhangH.LiuJ.XuM.HuH.LiY.ZhaoL.LiW.SunX.The anti-influenza virus drug, arbidol is an efficient inhibitor of SARS-CoV-2 in vitroCell Discov.628202010.1038/s41421-020-0169-8719582132373347Search in Google Scholar
Wang X., Xu W., Hu G., Xia S., Sun Z., Liu Z., Xie Y., Zhang R., Jiang S., Lu L.: SARS-CoV-2 infects T lymphocytes through its spike protein-mediated membrane fusion. Cell. Mol. Immunol. RETRACTED (2020)WangX.XuW.HuG.XiaS.SunZ.LiuZ.XieY.ZhangR.JiangS.LuL.SARS-CoV-2 infects T lymphocytes through its spike protein-mediated membrane fusionCell. Mol. Immunol.RETRACTED202010.1038/s41423-020-0498-4734856332651469Search in Google Scholar
Wang Y., He Z. et al.: Inhibition of the infectivity and inflammatory response of influenza virus by Arbidol hydrochloride in vitro and in vivo (mice and ferret). Biomed. Pharmacother. 91, 393–401 (2017)WangY.HeZ.Inhibition of the infectivity and inflammatory response of influenza virus by Arbidol hydrochloride in vitro and in vivo (mice and ferret)Biomed. Pharmacother.91393401201710.1016/j.biopha.2017.04.09128475918Search in Google Scholar
Wang Y., Guo D. et al.: Coronavirus nsp10/nsp16 methyltransferase can be targeted by nsp10-derived peptide in vitro and in vivo to reduce replication and pathogenesis. J. Virol. 89, 8416–8427 (2015)WangY.GuoD.Coronavirus nsp10/nsp16 methyltransferase can be targeted by nsp10-derived peptide in vitro and in vivo to reduce replication and pathogenesisJ. Virol.8984168427201510.1128/JVI.00948-15452425726041293Search in Google Scholar
Wang Y., Wang C. et al.: Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet, 395, 1569–1578 (2020)WangY.WangC.Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trialLancet39515691578202010.1016/S0140-6736(20)31022-9719030332423584Search in Google Scholar
Wang Y., Wang C. et al.: Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet, 395, 1569–1578 (2020)WangY.WangC.Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trialLancet39515691578202010.1016/S0140-6736(20)31022-9Search in Google Scholar
Wang Z., Chen X., Lu Y., Chen F., Zhang W.: Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicine treatment. BioScience Trends, 14, 64–68 (2020)WangZ.ChenX.LuY.ChenF.ZhangW.Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicine treatmentBioScience Trends146468202010.5582/bst.2020.0103032037389Search in Google Scholar
Williamson B.N., de Wit E. et al.: Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2. bioRxiv, 2020.2004.2015.043166 (2020)WilliamsonB.N.de WitE.Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2bioRxiv2020.2004.2015.043166202010.1038/s41586-020-2423-5748627132516797Search in Google Scholar
Wrapp D., Wang N., Corbett K.S., Goldsmith J.A., Hsieh C.-L., Abiona O., Graham B.S., McLellan J.S.: Cryo-EM Structure of the 2019-nCoV Spike in the Prefusion Conformation. bioRxiv, 2020.2002.2011.944462 (2020)WrappD.WangN.CorbettK.S.GoldsmithJ.A.HsiehC.-L.AbionaO.GrahamB.S.McLellanJ.S.Cryo-EM Structure of the 2019-nCoV Spike in the Prefusion ConformationbioRxiv2020.2002.2011.944462202010.1126/science.abb2507716463732075877Search in Google Scholar
Wujtewicz M., Dylczyk-Sommer A., Aszkiełowicz A., Zdanowski S., Piwowarczyk S., Owczuk R.: COVID-19 – what should anaethesiologists and intensivists know about it? Anaesthesiol. Intensive Ther. 52, 34–41 (2020)WujtewiczM.Dylczyk-SommerA.AszkiełowiczA.ZdanowskiS.PiwowarczykS.OwczukR.COVID-19 – what should anaethesiologists and intensivists know about it?Anaesthesiol. Intensive Ther.523441202010.5114/ait.2020.9375632191830Search in Google Scholar
Xia S., Lu L. et al.: Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion. Cell Res. 30, 343–355 (2020)XiaS.LuL.Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusionCell Res.30343355202010.1038/s41422-020-0305-x710472332231345Search in Google Scholar
Xia S., Lu L. et al.: A pan-coronavirus fusion inhibitor targeting the HR1 domain of human coronavirus spike. Sci. Adv. 5, eaav4580 (2019)XiaS.LuL.A pan-coronavirus fusion inhibitor targeting the HR1 domain of human coronavirus spikeSci. Adv.5eaav4580201910.1126/sciadv.aav4580645793130989115Search in Google Scholar
Xu J., Zhao S., Teng T., Abdalla A.E., Zhu W., Xie L., Wang Y., Guo X.: Systematic Comparison of Two Animal-to-Human Transmitted Human Coronaviruses: SARS-CoV-2 and SARS-CoV. Viruses, 12, 244 (2020)XuJ.ZhaoS.TengT.AbdallaA.E.ZhuW.XieL.WangY.GuoX.Systematic Comparison of Two Animal-to-Human Transmitted Human Coronaviruses: SARS-CoV-2 and SARS-CoVViruses12244202010.3390/v12020244707719132098422Search in Google Scholar
Xu P., Huang J., Fan Z., Huang W., Qi M., Lin X., Song W., Yi L.: Arbidol/IFN-α2b therapy for patients with corona virus disease 2019: a retrospective multicenter cohort study. Microbes Infect. 22, 200–205 (2020)XuP.HuangJ.FanZ.HuangW.QiM.LinX.SongW.YiL.Arbidol/IFN-α2b therapy for patients with corona virus disease 2019: a retrospective multicenter cohort studyMicrobes Infect.22200205202010.1016/j.micinf.2020.05.012723899132445881Search in Google Scholar
Xu X., Wei H. et al.: Effective treatment of severe COVID-19 patients with tocilizumab. Proc. Nat Acad. Sci. USA, 117, 10970 (2020)XuX.WeiH.Effective treatment of severe COVID-19 patients with tocilizumabProc. Nat Acad. Sci. USA11710970202010.1073/pnas.2005615117724508932350134Search in Google Scholar
Yamamoto M., Matsuyama S., Li X., Takeda M., Kawaguchi Y., Inoue J.-I., Matsuda Z.: Identification of Nafamostat as a Potent Inhibitor of Middle East Respiratory Syndrome Coronavirus S Protein-Mediated Membrane Fusion Using the Split-Protein-Based Cell-Cell Fusion Assay. Antimicrob. Agents Chemother. 60, 6532–6539 (2016)YamamotoM.MatsuyamaS.LiX.TakedaM.KawaguchiY.InoueJ.-I.MatsudaZ.Identification of Nafamostat as a Potent Inhibitor of Middle East Respiratory Syndrome Coronavirus S Protein-Mediated Membrane Fusion Using the Split-Protein-Based Cell-Cell Fusion AssayAntimicrob. Agents Chemother.6065326539201610.1128/AAC.01043-16507505627550352Search in Google Scholar
Yang Y., Ye F., Zhu N., Wang W., Deng Y., Zhao Z., Tan W.: Middle East respiratory syndrome coronavirus ORF4b protein inhibits type I interferon production through both cytoplasmic and nuclear targets. Sci. Rep. 5, 17554 (2015)YangY.YeF.ZhuN.WangW.DengY.ZhaoZ.TanW.Middle East respiratory syndrome coronavirus ORF4b protein inhibits type I interferon production through both cytoplasmic and nuclear targetsSci. Rep.517554201510.1038/srep17554466836926631542Search in Google Scholar
Yao X., Liu D. et al.: In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Clin. Infect. Dis. ciaa237 (2020)YaoX.LiuD.In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)Clin. Infect. Dis.ciaa237202010.1093/cid/ciaa237710813032150618Search in Google Scholar
Yin W., Xu H.E. et al.: Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir. Science, 368, 1499–1504 (2020)YinW.XuH.E.Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivirScience36814991504202010.1126/science.abc1560719990832358203Search in Google Scholar
Yokota S., Miyamae T., Imagawa T., Iwata N., Katakura S., Mori M., Woo P., Nishimoto N., Yoshizaki K., Kishimoto T.: Therapeutic efficacy of humanized recombinant anti-interleukin-6 receptor antibody in children with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum. 52, 818–825 (2005)YokotaS.MiyamaeT.ImagawaT.IwataN.KatakuraS.MoriM.WooP.NishimotoN.YoshizakiK.KishimotoT.Therapeutic efficacy of humanized recombinant anti-interleukin-6 receptor antibody in children with systemic-onset juvenile idiopathic arthritisArthritis Rheum.52818825200510.1002/art.2094415751095Search in Google Scholar
Zhang C., Wu Z., Li J.-W., Zhao H., Wang G.-Q.: The cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist Tocilizumab may be the key to reduce the mortality. Int. J. Antimicrob. Agents, 55, 105954–105954 (2020)ZhangC.WuZ.LiJ.-W.ZhaoH.WangG.-Q.The cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist Tocilizumab may be the key to reduce the mortalityInt. J. Antimicrob. Agents55105954105954202010.1016/j.ijantimicag.2020.105954711863432234467Search in Google Scholar
Zhang P., Wang F. et al.: The novel coronavirus (COVID-19) pneumonia with negative detection of viral ribonucleic acid from nasopharyngeal swabs: a case report. BMC Infect. Dis. 20, 317–317 (2020)ZhangP.WangF.The novel coronavirus (COVID-19) pneumonia with negative detection of viral ribonucleic acid from nasopharyngeal swabs: a case reportBMC Infect. Dis.20317317202010.1186/s12879-020-05045-z719155532354369Search in Google Scholar
Zhou P., Yang X.-L., Wang X.-G., Hu B., Zhang L., Zhang W., Si H.-R., Zhu Y., Li B., Huang C.-L. et al.: A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature, 579, 270–273 (2020)ZhouP.YangX.-L.WangX.-G.HuB.ZhangL.ZhangW.SiH.-R.ZhuY.LiB.HuangC.-L.A pneumonia outbreak associated with a new coronavirus of probable bat originNature579270273202010.1038/s41586-020-2012-7709541832015507Search in Google Scholar
Zhou Y., Simmons G. et al.: Protease inhibitors targeting coronavirus and filovirus entry. Antiviral Res. 116, 76–84 (2015)ZhouY.SimmonsG.Protease inhibitors targeting coronavirus and filovirus entryAntiviral Res.1167684201510.1016/j.antiviral.2015.01.011477453425666761Search in Google Scholar
Zhu Z., Lu Z., Xu T., Chen C., Yang G., Zha T., Lu J., Xue Y.: Arbidol monotherapy is superior to lopinavir/ritonavir in treating COVID-19. J. Infect. 81, e21–e23 (2020)ZhuZ.LuZ.XuT.ChenC.YangG.ZhaT.LuJ.XueY.Arbidol monotherapy is superior to lopinavir/ritonavir in treating COVID-19J. Infect.81e21e23202010.1016/j.jinf.2020.03.060719539332283143Search in Google Scholar
Zinter M.S., Hermiston M.L.: Calming the storm in HLH. Blood, 134, 103–104 (2019)ZinterM.S.HermistonM.L.Calming the storm in HLHBlood134103104201910.1182/blood.201900133331296541Search in Google Scholar
Zou Z., Jiang C. et al.: Angiotensin-converting enzyme 2 protects from lethal avian influenza A H5N1 infections. Nat. Commun. 5, 3594–3594 (2014)ZouZ.JiangC.Angiotensin-converting enzyme 2 protects from lethal avian influenza A H5N1 infectionsNat. Commun.535943594201410.1038/ncomms4594709184824800825Search in Google Scholar
